(2,6-dichloro-phenyl)-propiolic acid | 24653-88-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2,6-dichloro-phenyl)-propiolic acid
• 英文别名: (2,6-Dichlor-phenyl)-propiolsaeure；(2,6-dichlorophenyl)-propargylic acid；3-(2,6-dichlorophenyl)prop-2-ynoic acid
• CAS: 24653-88-1
• 化学式: C₉H₄Cl₂O₂
• 分子量: 215.036
• InChiKey: ZEWIXNAZIYWKOK-UHFFFAOYSA-N

物化性质

• 熔点：
  167-168 °C
• 沸点：
  373.7±42.0 °C(Predicted)
• 密度：
  1.53±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2,6-dichloro-phenyl)-propiolic acid 在 溴 作用下， 生成 α,β-dibromo-2,6-dichloro-cinnamic acid
  参考文献：
  名称：

  Reich, Bulletin de la Societe Chimique de France, 1917, vol. <4> 21, p. 222

  摘要：

  DOI：
• 作为产物：
  描述：

  1,1-二乙酰氧基-1-(2,6-二氯苯基)甲烷 在 氢氧化钾 、 溴 、 sodium acetate 、 溶剂黄146 作用下， 生成 (2,6-dichloro-phenyl)-propiolic acid
  参考文献：
  名称：

  Reich, Bulletin de la Societe Chimique de France, 1917, vol. <4> 21, p. 222

  摘要：

  DOI：

文献信息

• 2-Amino-6-anilino-purines and their use as medicaments
  申请人：——

  公开号：US20020016329A1

  公开（公告）日：2002-02-07

  2-Amino-6-anilino-purine derivatives of the formula I 1 in which the symbols are as defined in claim 1, are described. These compounds inhibit p34 cdc2 /cyclin B cdc13 kinase and protein tyrosine kinase pp60 c-src and can be used for treatment of hyperproliferative diseases, for example tumor diseases, and diseases which respond to inhibition of the activity of protein tyrosine kinase pp60 c-src , in particular osteoporosis.

  公式I中定义的符号如权利要求书1中所定义的那样，描述了1的2-氨基-6-苯胺基嘌呤衍生物。这些化合物抑制p34 cdc2/cyclin B cdc13激酶和蛋白酪氨酸激酶pp60 c-src，并可用于治疗过度增殖性疾病，例如肿瘤疾病，以及对蛋白酪氨酸激酶pp60 c-src活性抑制有反应的疾病，特别是骨质疏松症。
• 2-amino-6-anilino-purines and their use as medicaments
  申请人：Novartis AG

  公开号：US06767906B2

  公开（公告）日：2004-07-27

  This application discloses 2-amino-6-anilino-purine derivatives of the formula I in which q is 1-5, and R1 is &agr;) —S(═O)k—NR6R7, in which  k is 1 or 2,  wherein under the proviso that R6 and R7 cannot be simultaneously hydrogen &agr;1) R6, R7 can be identical or different from one another and represent an aliphatic, carbocyclic, heterocyclic, carbocyclic-aliphatic or heterocyclic-aliphatic radical; hydrogen or lower aliphatic acyl; or &agr;2) R6 and R7 together are an alkylene or alkenylene radical having from 3 up to and including 9 C atoms, in which 1-3 C atoms can be replaced by oxygen, sulfur or nitrogen, &bgr;) N-(aryl lower alkyl)carbamoyl, or &ggr;) a radical of the formula —NH—S(═O)i—R8, in which  i is 1 or 2,  R8 is an aliphatic, carbocyclic or heterocyclic radical; or &dgr;) a radical of the formula —NH—C(═O)—R9,  and the other variable substituents are as defined herein. The inventive compounds inhibit p34cdc2/cyclin Bcdc13 kinase and protein tyrosine kinase pp60c-src and can be used for treatment of hyperproliferative diseases, for example tumour diseases, and diseases which respond to inhibition of the activity of protein tyrosine kinase pp60c-src, in particular osteoporosis.

  本申请公开了式I的2-氨基-6-苯胺基嘌呤衍生物，其中q为1-5，R1为&agr;) -S（═O）k-NR6R7，其中k为1或2，在R6和R7不能同时为氢的前提下&agr;1）R6，R7可以相同或不同，表示脂肪族，环烷，杂环，环烷基-脂肪族或杂环-脂肪族基；氢或较低的脂肪酰基；或&agr;2）R6和R7在一起是具有3到9个C原子的烷基或烯基基团，其中1-3个C原子可以被氧，硫或氮取代，&bgr;) N-（芳基较低烷基）氨基甲酰基，或&ggr;) 公式-NH-S（═O）i-R8的基团，在其中i为1或2，R8为脂肪族，环烷或杂环基团；或&dgr;) 公式-NH-C（═O）-R9的基团，其它可变取代基的定义如本文所述。这些创新化合物抑制p34cdc2 / cyclin Bcdc13激酶和蛋白酪氨酸激酶pp60c-src，并可用于治疗增生性疾病，例如肿瘤疾病和对蛋白酪氨酸激酶pp60c-src活性抑制有反应的疾病，特别是骨质疏松症。
• 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS
  申请人：Novartis AG

  公开号：EP1153024B1

  公开（公告）日：2004-04-28
• US6767906B2
  申请人：——

  公开号：US6767906B2

  公开（公告）日：2004-07-27
• [EN] 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS<br/>[FR] 2-AMINO-6-ANILINO-PURINES ET LEUR UTILISATION COMME MEDICAMENTS
  申请人：NOVARTIS AG

  公开号：WO2000049018A1

  公开（公告）日：2000-08-24

  2-Amino-6-anilino-purine derivatives of formula (I) in which R1 is -S(O)k-NR6R7 or-N(aryl lower alkyl) carbamoyl or -NH-S(O)i-R8 or -NH-C(O)-R9; 9 is 1-5; These compounds inhibit p34cdc2/cyclin Bcdc13 kinase and protein tyrosine kinase pp60c-src and can be used for treatment of hyperproliferative diseases, for example tumour diseases, and diseases which respond to inhibition of the activity of protein tyrosine kinase pp60c-src, in particular osteoporosis.